Follistatin
Research OnlyAlso known as: FST, FS-344, FS-315, Activin-Binding Protein
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
Research Statistics
Mostly preclinical; well-characterized myostatin-inhibiting mechanism but limited human data.
Research Dossier
Overview
What is Follistatin and what does the research say?
Mechanism of Action
Follistatin’s mechanisms are well-characterized through structural biology and gene therapy trials, though injectable peptide effects in humans remain unvalidated.
How It Works (Simplified)
Follistatin acts as a “molecular sponge” that neutralizes muscle-limiting proteins:
Binds and sequesters myostatin (GDF-8), the body’s primary muscle growth limiter, preventing it from signaling muscles to stop growing.
Binds activin A with extremely high affinity (Kd ~45 pM), reducing catabolic signaling that promotes muscle wasting.
Two follistatin molecules encircle each ligand, physically blocking access to ActRIIA/ActRIIB receptors on muscle cells.
Hypertrophic effects require functional IGF-1 receptor signaling; follistatin removes inhibition rather than directly stimulating growth.
Scientific Pathways
Myostatin/Activin Sequestration Pathway (Primary mechanism)
Follistatin (2 molecules) → Encircle myostatin/activin dimer → Block receptor sites
↓
Reduced Smad2/3 phosphorylation → Muscle hypertrophyIGF-1R Requirement (Necessary for effect)
Follistatin → Myostatin inhibition → Requires IGF-1R/Akt/mTOR intact → Full hypertrophic response
|
IGF-IR inhibition reduces effect by ~63%Key Research: Crystal structures PMID:16198295 and gene therapy trials PMID:25322757 confirm mechanism.
Important Limitations
- All human efficacy data comes from gene therapy (AAV delivery), not injectable peptides
- Native follistatin has very short half-life (~4 min initial, ~130 min terminal) limiting systemic effects
- Gene therapy produces sustained local expression; peptide injection kinetics are entirely different
- Black market FS-344/FS-315 products have significant quality issues (WADA found only 9/17 contained follistatin)
- Translation from gene therapy success to injectable peptide effects is not scientifically supported
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Native follistatin has very short half-life (~4 min initial, ~130 min terminal). Injectable peptide effects would be transient. Gene therapy produces sustained local expression over months to years.
In AAV gene therapy trials, muscle improvements were observed over 6-12 months and maintained for 15+ months in primate studies. This timeline is specific to gene therapy, not peptide injection.
Long-term safety of sustained myostatin inhibition is uncertain. Concerns include effects on cardiac muscle, tendons, and other tissues. Gene therapy trials continue to monitor safety.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Follistatin product quality
Good Signs (4 indicators)
Warning Signs (4 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Follistatin with other peptides. Based on published research and mechanistic considerations.
Igf-1-Lr3
SynergisticFollistatin's hypertrophic effects require intact IGF-1R/Akt/mTOR pathway. IGF-1 LR3 activates this pathway directly. Combined use may amplify muscle growth but also compounds unknown risks.
Hgh
CompatibleHGH increases IGF-1, which is required for follistatin's full effect. Theoretical synergy, but combined safety not established.
BPC-157
CompatibleDifferent regenerative targets - follistatin for muscle growth via myostatin inhibition, BPC-157 for tissue healing. No known interactions.
TB-500
CompatibleDifferent mechanisms - TB-500 for tissue repair via actin regulation, follistatin for muscle growth via myostatin/activin sequestration.
Follistatin already inhibits myostatin. Adding other myostatin inhibitors is redundant and may cause unpredictable effects on the activin/myostatin/follistatin balance.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Follistatin
Follistatin Calculators
Related Peptides
CJC-1295
DAC:GRF, Modified GRF 1-29, Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
GHRP-2
Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6, SKF-110679, Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG, Choriogonadotropin, Pregnyl +5 more
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin, HEX, Growth Hormone Releasing Hexapeptide +2 more
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
HMG
Human Menopausal Gonadotropin, Menotropins, hMG +4 more
A urinary-derived glycoprotein hormone preparation containing both FSH and LH in approximately 1:1 ratio, FDA-approved for female infertility (ovulation induction, ART) and male hypogonadotropic hypogonadism. First used clinically in 1961 by Bruno Lunenfeld, HMG enabled the birth of the first American IVF baby in 1981 and remains a cornerstone of fertility medicine with over 60 years of clinical experience. Highly purified preparations (HP-hMG) demonstrate comparable or slightly superior live birth rates compared to recombinant FSH in IVF.